Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

3/19/2026

Janusmed kön och genus

Janusmed kön och genus – Ocrevus

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Okrelizumab Testmiljö

Okrelizumab

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Ocrevus (ocrelizumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-02-13, cited 2026-02-11].

  2. Bove R, Chitnis T. The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler. 2014;20:520-6.

  3. Voskuhl RR, Gold SM. Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol. 2012;8:255-63.

  4. Johnson KM, Zhou H, Lin F, Ko JJ, Herrera V. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year. J Manag Care Spec Pharm. 2017;23:844-852.

  5. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol. 2007;6(10):903-12.

  6. Ocrevus (ocrelizumab). EPAR Risk management plan. European Medicines Agency (EMA) [www]. [updated 2025-12-17, cited 2026-02-13].

  7. Al-Temaimi R, AbuBaker J, Al-Khairi I, Alroughani R. Remyelination modulators in multiple sclerosis patients. Exp Mol Pathol. 2017;103(3):237-241.

  8. Gibiansky E, Petry C, Mercier F, Günther A, Herman A, Kappos L et al. Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. Br J Clin Pharmacol. 2021;87(6):2511-2520.

  9. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - Ocrevus (ocrelizumab). Drugs@FDA [www]. [updated 2016-09-16, cited 2026-02-13].

  10. Food and Drug Administration (FDA). Prescribing information - Ocrevus (ocrelizumab). Drugs@FDA [www]. [updated 2025-08-01, cited 2026-02-12].

  11. Turner B, Cree BAC, Kappos L, Montalban X, Papeix C, Wolinsky JS et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol. 2019;266(5):1182-1193.

  12. Food and Drug Administration (FDA). Medical review - Ocrevus (okrelizumab). Drugs@FDA [www]. [updated 2016-09-12, cited 2026-02-12].

  13. Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C et al. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Ann Neurol. 2018;84(4):527-536.

  14. Zaccone T, Moiola L, Guerrieri S, Nozzolillo A, Zanetta C, Gattuso I et al. Long-term effectiveness and safety of ocrelizumab: a single-centre real-world study. J Neurol. 2025;272(7):481.

  15. Hay M, Rollot F, Casey R, Kerbrat A, Edan G, Mathey G et al. Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study. Neurology. 2024;103(8):e209886.

  16. Davies L, Shehadeh R, Watkins WJ, Jolles S, Robertson NP, Tallantyre EC. Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis. J Neurol. 2025;272(6):415.

  17. Karaman B, Dinçer G, Tunçel R, Ekmekci O, Yüceyar N. Secondary hypogammaglobulinemia and lymphocytopenia in patients with inflammatory neurological diseases on anti-CD20 therapy: risk of infection and infection-related mortality. Neurol Sci. 2025;46(9):4569-4574.

  18. Peters J, Longbrake EE. Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease. Mult Scler Relat Disord. 2022;68:104400.

  19. Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol. 2020;7(9):1477-1487.

  20. Conte WL, Arndt N, Cipriani VP, Dellaria A, Javed A. Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol. Mult Scler Relat Disord. 2019;27:397-399.

  21. Hammer H, Kamber N, Pistor M, Diem L, Friedli C, Chan A et al. Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS). Mult Scler Relat Disord. 2022;65:104015.

  1. Ocrevus (ocrelizumab). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2025-02-13, cited 2026-02-11].
  2. Bove R, Chitnis T. The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler. 2014;20:520-6.
  3. Voskuhl RR, Gold SM. Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol. 2012;8:255-63.
  4. Johnson KM, Zhou H, Lin F, Ko JJ, Herrera V. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year. J Manag Care Spec Pharm. 2017;23:844-852.
  5. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol. 2007;6(10):903-12.
  6. Ocrevus (ocrelizumab). EPAR Risk management plan. European Medicines Agency (EMA) [www]. [updated 2025-12-17, cited 2026-02-13].
  7. Al-Temaimi R, AbuBaker J, Al-Khairi I, Alroughani R. Remyelination modulators in multiple sclerosis patients. Exp Mol Pathol. 2017;103(3):237-241.
  8. Gibiansky E, Petry C, Mercier F, Günther A, Herman A, Kappos L et al. Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. Br J Clin Pharmacol. 2021;87(6):2511-2520.
  9. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - Ocrevus (ocrelizumab). Drugs@FDA [www]. [updated 2016-09-16, cited 2026-02-13].
  10. Food and Drug Administration (FDA). Prescribing information - Ocrevus (ocrelizumab). Drugs@FDA [www]. [updated 2025-08-01, cited 2026-02-12].
  11. Turner B, Cree BAC, Kappos L, Montalban X, Papeix C, Wolinsky JS et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. J Neurol. 2019;266(5):1182-1193.
  12. Food and Drug Administration (FDA). Medical review - Ocrevus (okrelizumab). Drugs@FDA [www]. [updated 2016-09-12, cited 2026-02-12].
  13. Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C et al. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Ann Neurol. 2018;84(4):527-536.
  14. Zaccone T, Moiola L, Guerrieri S, Nozzolillo A, Zanetta C, Gattuso I et al. Long-term effectiveness and safety of ocrelizumab: a single-centre real-world study. J Neurol. 2025;272(7):481.
  15. Hay M, Rollot F, Casey R, Kerbrat A, Edan G, Mathey G et al. Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study. Neurology. 2024;103(8):e209886.
  16. Davies L, Shehadeh R, Watkins WJ, Jolles S, Robertson NP, Tallantyre EC. Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis. J Neurol. 2025;272(6):415.
  17. Karaman B, Dinçer G, Tunçel R, Ekmekci O, Yüceyar N. Secondary hypogammaglobulinemia and lymphocytopenia in patients with inflammatory neurological diseases on anti-CD20 therapy: risk of infection and infection-related mortality. Neurol Sci. 2025;46(9):4569-4574.
  18. Peters J, Longbrake EE. Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease. Mult Scler Relat Disord. 2022;68:104400.
  19. Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol. 2020;7(9):1477-1487.
  20. Conte WL, Arndt N, Cipriani VP, Dellaria A, Javed A. Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol. Mult Scler Relat Disord. 2019;27:397-399.
  21. Hammer H, Kamber N, Pistor M, Diem L, Friedli C, Chan A et al. Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS). Mult Scler Relat Disord. 2022;65:104015.